AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32209798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking exercise (NW) for 12 weeks, 1 hour 3 times a week at 60-70% of maximal heart rate
Number of subjects: 30
Study 32209798 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lower-calorie diet (MD) for 12 weeks, reducing daily energy intake by 30%
Number of subjects: 30
Study 35437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver
Number of subjects: 11
Study 35437136 — intervention group
Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 11
Study 35437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver with chest compression
Number of subjects: 11
Study 35437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver with cervical stabilization
Number of subjects: 11
Study 35437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver without chest compression
Number of subjects: 11
Study 35437136 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver without cervical stabilization
Number of subjects: 11
Study 35437136 — intervention group
Group type: COMPARATOR
Intervention: Standard method with chest compression
Number of subjects: 11
Study 35437136 — intervention group
Group type: COMPARATOR
Intervention: Standard method with cervical stabilization
Number of subjects: 11
Study 35437136 — intervention group
Group type: COMPARATOR
Intervention: Standard method without chest compression
Number of subjects: 11
Study 35437136 — intervention group
Group type: COMPARATOR
Intervention: Standard method without cervical stabilization
Number of subjects: 11
Study 33187020 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile general anaesthesia (GA)
Number of subjects: 40
Study 33187020 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol GA combined with paravertebral regional anaesthesia (PPA)
Number of subjects: 40
Study 33187020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 32496449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.004 mg/kg intravenously
Number of subjects: 120
Study 32496449 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study 33188598 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 1859
Study 33188598 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Revascularization (ICR)
Number of subjects: 1859
Study 32898569 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization with Carfilzomib (27mg/m2 IV) and Lulizumab (12.5mg/kg SC) over four weeks
Number of subjects: 10
Study 32898569 — intervention group
Group type: COMPARATOR
Intervention: No desensitization (Control)
Number of subjects: 10
Study 32645683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS (10 Hz, 2 mA, 30 min) combined with ABM
Number of subjects: 19
Study 32645683 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS combined with ABM
Number of subjects: 19
Study 35086737 — intervention group
Group type: EXPERIMENTAL
Intervention: pharmacogenomic-driven chemotherapy
Number of subjects: 0
Study 35086737 — intervention group
Group type: COMPARATOR
Intervention: standard adjuvant chemotherapy
Number of subjects: 0
Study 33314605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-layered silicone foam
Number of subjects: 135
Study 33314605 — intervention group
Group type: COMPARATOR
Intervention: Transparent polyurethane film
Number of subjects: 135
Study 34768502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal gymnastics (HAG)
Number of subjects: 40
Study 34768502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 32536013 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg twice daily) plus nonsteroidal aromatase inhibitor (NSAI)
Number of subjects: 493
Study 32536013 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal aromatase inhibitor (NSAI)
Number of subjects: 493
Study 32536013 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus NSAI
Number of subjects: 493
Study 35266417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (20 mg subcutaneously every 4 weeks)
Number of subjects: 615
Study 35266417 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide (14 mg orally once daily)
Number of subjects: 615
Study 32272959 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 μg misoprostol sublingually
Number of subjects: 200
Study 32272959 — intervention group
Group type: COMPARATOR
Intervention: 25 μg misoprostol vaginally
Number of subjects: 200
Study 35086385 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA) with adjunctive drug-coated balloon (DCB) angioplasty
Number of subjects: 66
Study 35086385 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA) and DCB angioplasty (control)
Number of subjects: 66
Study 35086385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 34837899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions every 2 days
Number of subjects: 32
Study 34837899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 35655176 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing breathing
Number of subjects: 34
Study 35655176 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing breathing paired with cardiac biofeedback
Number of subjects: 34
Study 35655176 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 36296976 — intervention group
Group type: EXPERIMENTAL
Intervention: Web resource (access to IBD-specific diet concerns) for 12 weeks
Number of subjects: 50
Study 36296976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to web resource) for 12 weeks
Number of subjects: 50
Study 36296976 — intervention group
Group type: EXPERIMENTAL
Intervention: Web resource
Number of subjects: 50
Study 36296976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 33212988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health variables (psychological symptoms, financial difficulties, psychological disorders)
Number of subjects: 555
Study 33212988 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and mental disorders
Number of subjects: 555
Study 33212988 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of psychological symptoms
Number of subjects: 555
Study 33212988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 555
Study 35041337 — intervention group
Group type: COMPARATOR
Intervention: Resection of the primary (RP) in small intestine tumors
Number of subjects: 2361
Study 35041337 — intervention group
Group type: COMPARATOR
Intervention: Resection of the primary (RP) in lung tumors
Number of subjects: 2361
Study 35041337 — intervention group
Group type: COMPARATOR
Intervention: Resection of the primary (RP) in pancreas tumors
Number of subjects: 2361
Study 35041337 — intervention group
Group type: COMPARATOR
Intervention: Resection of the primary (RP) overall
Number of subjects: 2361
Study 35973395 — intervention group
Group type: EXPERIMENTAL
Intervention: P1016 (endopeptidase)
Number of subjects: 23
Study 35973395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32920647 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP‐XR (extended-release subcutaneous buprenorphine)
Number of subjects: 454
Study 32920647 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 454
Study 32272973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU)
Number of subjects: 24
Study 35853489 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injection of pegcetacoplan (AM)
Number of subjects: 113
Study 35853489 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection every other month of pegcetacoplan (AEOM)
Number of subjects: 113
Study 35853489 — intervention group
Group type: COMPARATOR
Intervention: Sham control (SM)
Number of subjects: 113
Study 35853489 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 113
Study 34342501 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 339
Study 34342501 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-prompted core-needle biopsies (CNBs)
Number of subjects: 339
Study 34342501 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 339
Study 34342501 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI features
Number of subjects: 339
Study 33010126 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program and pain management protocol (after intervention)
Number of subjects: 261
Study 36395809 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction SABR (SF)
Number of subjects: 87
Study 33958326 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE Q4W
Number of subjects: 155
Study 33958326 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE Q2W
Number of subjects: 155
Study 33958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IXE
Number of subjects: 155
Study 33958326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 155
Study 32401905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention to reduce alcohol use
Number of subjects: 132
Study 32401905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention to increase HIV knowledge
Number of subjects: 132
Study 32401905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention to increase condom use self-efficacy
Number of subjects: 132
Study 32401905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 132
Study 36367998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZA) 160 mg once daily for 6 months
Number of subjects: 86
Study 36367998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 36367998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZA)
Number of subjects: 86
Study 33432386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence angiography (FA)
Number of subjects: 0
Study 33432386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33432386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging
Number of subjects: 0
Study 33432386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) sentinel lymph node (SLN) detection
Number of subjects: 0
Study 33432386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) visualization
Number of subjects: 0
Study 34666767 — intervention group
Group type: EXPERIMENTAL
Intervention: JTA-200/2 (200 μg clonidine and 20 mg hyaluronic acid in 2 ml)
Number of subjects: 164
Study 34666767 — intervention group
Group type: EXPERIMENTAL
Intervention: JTA-004 (pooled data from all formulations)
Number of subjects: 164
Study 34666767 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment (hylan G-F 20)
Number of subjects: 164
Study 33212467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex Workers
Number of subjects: 60
Study 33212467 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 34922888 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal transradial approach (dTRA)
Number of subjects: 1042
Study 34922888 — intervention group
Group type: COMPARATOR
Intervention: Traditional transradial approach (TRA)
Number of subjects: 1042
Study 34108127 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib/dexamethasone (D‐Vd)
Number of subjects: 211
Study 34108127 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 211
Study 35794728 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloring therapy combined with conventional therapy
Number of subjects: 88
Study 35794728 — intervention group
Group type: COMPARATOR
Intervention: Conventional antianxiety medication and physical therapy
Number of subjects: 88
Study 34039734 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral triangle block and iPACK
Number of subjects: 60
Study 34039734 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia
Number of subjects: 60
Study 32362479 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen patch (FPP)
Number of subjects: 79
Study 32362479 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Flurbiprofen patch (SFPP)
Number of subjects: 79
Study 32362479 — intervention group
Group type: COMPARATOR
Intervention: Control (no patch)
Number of subjects: 79
Study 36323482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care approach including app-intervention, two telephone counselling sessions (50 min each), and online therapy over 17 weeks (15 weekly group sessions, 8 individual sessions).
Number of subjects: 860
Study 36323482 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (details not specified in the abstract).
Number of subjects: 860
Study 34266940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 and 300 mg every 2 weeks
Number of subjects: 0
Study 34266940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33079959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi (104 CFU)
Number of subjects: 0
Study 33079959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella Paratyphi A (103 CFU)
Number of subjects: 0
Study 33079959 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exposure to Salmonella Typhi or Paratyphi A
Number of subjects: 0
Study 33079959 — intervention group
Group type: COMPARATOR
Intervention: Naïve controls
Number of subjects: 0
Study 33079959 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous re-challenge with Salmonella Typhi or Salmonella Paratyphi A
Number of subjects: 0
Study 33079959 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure
Number of subjects: 0
Study 35765748 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week attention training
Number of subjects: 82
Study 35765748 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 82
Study 33291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent support program
Number of subjects: 128
Study 33291185 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 128
Study 33291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline parental depression
Number of subjects: 128
Study 35623315 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/d)
Number of subjects: 23
Study 35623315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32917922 — intervention group
Group type: EXPERIMENTAL
Intervention: Leftward attentional shift (prismatic adaptation)
Number of subjects: 54
Study 32917922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rightward attentional shift (prismatic adaptation)
Number of subjects: 54
Study 35988464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum azithromycin (2g oral)
Number of subjects: 109
Study 35988464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 34823296 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation alone (282 patients)
Number of subjects: 848
Study 34823296 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (281 patients)
Number of subjects: 848
Study 34823296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy (285 patients)
Number of subjects: 848
Study 34823296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (848 patients)
Number of subjects: 848
Study 32540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 516
Study 32540325 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 516
Study 32540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral disease (yes vs. no)
Number of subjects: 516
Study 32540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline intraocular pressure (IOP)
Number of subjects: 516
Study 32540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc hemorrhage at visit 1
Number of subjects: 516
Study 32540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (current or previous)
Number of subjects: 516
Study 34713987 — intervention group
Group type: EXPERIMENTAL
Intervention: PB2452 6 g i.v. bolus followed by 6 g infused over 4 h and then 6 g over 12 h
Number of subjects: 61
Study 34713987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33142034 — intervention group
Group type: EXPERIMENTAL
Intervention: Keilland’s forceps delivery
Number of subjects: 971
Study 33142034 — intervention group
Group type: COMPARATOR
Intervention: Primary full dilation caesarean section
Number of subjects: 971
Study 36066009 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder (n = 44)
Number of subjects: 131
Study 36066009 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder (n = 42)
Number of subjects: 131
Study 36066009 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n = 45)
Number of subjects: 131
Study 33586134 — intervention group
Group type: EXPERIMENTAL
Intervention: PSR model based on independent preoperative and postoperative predictors
Number of subjects: 1076
Study 33586134 — intervention group
Group type: EXPERIMENTAL
Intervention: PSM model based on independent preoperative and postoperative predictors
Number of subjects: 1076
Study 32722807 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher γ' fibrinogen levels
Number of subjects: 0
Study 32722807 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total fibrinogen levels
Number of subjects: 0
Study 33731525 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTA + DES
Number of subjects: 332
Study 33731525 — intervention group
Group type: COMPARATOR
Intervention: ROTA + POBA
Number of subjects: 332
Study 33031472 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 113
Study 33031472 — intervention group
Group type: COMPARATOR
Intervention: External Fixation (EF)
Number of subjects: 113
Study 35817072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixagevimab–cilgavimab
Number of subjects: 1417
Study 35817072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1417
Study 33857436 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS with 36 mg/mL nicotine
Number of subjects: 520
Study 33857436 — intervention group
Group type: COMPARATOR
Intervention: Cigarette substitute (non-ENDS)
Number of subjects: 520
Study 33857436 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS with 0 mg/mL nicotine
Number of subjects: 520
Study 33857436 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS with 8 mg/mL nicotine
Number of subjects: 520
Study 32474156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 814
Study 32474156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 814
Study 32474156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 814
Study 36268807 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotec® herbal capsule (100 mg twice a day for three months)
Number of subjects: 103
Study 36268807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34837931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosamin spray (3-4 times a day)
Number of subjects: 80
Study 34837931 — intervention group
Group type: COMPARATOR
Intervention: Standard medications (3 times a day)
Number of subjects: 80
Study 35134800 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐SNEDDS containing medium‐chain triglyceride (FS1)
Number of subjects: 12
Study 35134800 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐SNEDDS containing long‐chain triglyceride (FS2)
Number of subjects: 12
Study 35134800 — intervention group
Group type: COMPARATOR
Intervention: Tablet of innovator product (FSt)
Number of subjects: 12
Study 33546734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of RAAS inhibitors
Number of subjects: 40
Study 33546734 — intervention group
Group type: COMPARATOR
Intervention: Temporary discontinuation of RAAS inhibitors
Number of subjects: 40
Study 32101501 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone (PEEK, Degos; G1)
Number of subjects: 48
Study 32101501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-ceramic composite (Lava Ultimate, 3M ESPE; G2)
Number of subjects: 48
Study 32101501 — intervention group
Group type: COMPARATOR
Intervention: Cast metal post (NiCr alloy, control; G3)
Number of subjects: 48
Study 32101501 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass post (Whitepost, FGM, control; G4)
Number of subjects: 48
Study 35696045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus cabozantinib
Number of subjects: 320
Study 35696045 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 320
Study 34580114 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus modified FOLFIRI (veliparib 200 mg twice daily, days 1-7 with mFOLFIRI days 3-5)
Number of subjects: 123
Study 34580114 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (control)
Number of subjects: 123
Study 34580114 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI in cancers with HR‐DDR defects
Number of subjects: 123
Study 34580114 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus mFOLFIRI in cancers with HR‐DDR defects
Number of subjects: 123
Study 36224739 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% O₂ + 4% CO₂
Number of subjects: 26
Study 36224739 — intervention group
Group type: COMPARATOR
Intervention: 6% O₂
Number of subjects: 26
Study 36224739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperventilation and hypoxia training
Number of subjects: 26
Study 34118783 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoclopramide + diphenhydramine
Number of subjects: 160